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tion time pmtong~ as ago incrennea and thus may plny a role in the lncreasod 
prevalence ol nlrlnl tibrlllallon In oldor ago groups, 
I 
1025 95 Froquoncy4OpOndont RO8 one0 Of Artorlal 
~amr~~optorr In Heart Fal uro: Prodomlnanco of P 
Modulation of Heart Rnto and Blood Prowro In 
tho Very Low Froquoncy Bando 
ln~ht~nl~ head Wwa (@IF). R pmlatQnt unlendkg 01 atladal baromcaptQrU 
(ABA) cantrIbutes IQ tha reduetlan al haart parlad (HP) and blmd prclalr~ 
(BP) variability in lhs low and hlgh tmqueney bend& Only In thfl vQly lQw 
trequanay (:O.Os Hx, VCF) larga llucluatlann Qt both HP and BP hava been 
da$cdbad, In Qrdar to mvssllgate A pesslble Irequeneydspsndent QftQ6~ Qt 
AIR on HP and BP, WI nppllsd a alnuanldnl nsakWItlQn (INS, fmm 0 ~CJ 
,-a0 mm=@) a\ taur dlamnt trequrnolaa (0.0% O.fN, O~l,O.~ HZ) In 7 nQt’n!ata 
(aga 4g $- la yra) and In 10 CHF patlanla) (aga 64 i 7, LVEF 24 4: B, NVHA 01, 
II-III). Renplranan was aantmlln:! dl o.PB Hz (tfi breMha/mln), In all sub@ats 
EC@, rsapiratlon, nQntnvaniva BP and SNS llms aerlaa were aQntlnuauslv 
reoort@d IQr a’ al basQlina and tar 4’ In tha SN9 tW’fIUliI~lQn trequsnaiea 
randamly appllsd, Tha rttaponas PI HP and dlaalollQ tlP ta ABR atimulatlan 
(aaasptad II oohamnaa -g,ft) tar balh normala and Cl-IF am rspaflad In tha 
tables 
0 N! HP am 0 a8 n: POP 0 i nr ~13r 0.2 nr gttr 
wrnt%f) tnrmt@t tmmtk$I tmmn$t 
NlVlllfll8 a4 t 03 00 t 0.4 22 t 04 a 
cnr: I32 122’ .l 3 t 1 3’ a4iol’ a 
(mnani S&t.‘-n. ooN 
The ponk rosponao 01 HP and BP lo SNS allmulallon was found 8~ 0.1 Hz 
wlh a minor attoct al ..O.l Hz in normals, while In CHF the peak was almllar 
In ampMtds but shlttod i3 lawor tmquenclas (0.02 and 0.05 Hz). 
Cmck?~n.c: In CHF, AEtR may sllll modulalo HP and BP varlablllty but 
only In lho very low balld ot Iho frequency spoclrum. This data suggests that 
nnalysls 01 ABA senslllvlly usually petlormed al 0.1 and 0.2 Hz Is kmllod In 
CHF pnllonls by tha lowpass oWocl 01 ADR msponse. 
1025-96 Heart Rate Varlablllty After Smoking Ceanatlon 
and ono Month Follow-up 
M. Yol&kura, Y. Koldo, A. Kalaynma. Ii. Ando. T. Yamaguchl. K. Sasatu, 
J. Surutu. K. Ishlkawa. I@otin Universily Tbkp Japan 
8a&gmur~? It Is known that hoarl rata varlablllly are increased aftor smoking 
cessallon. compared la the slate dolorminod during smokmg. but no work has 
o\or bean done concommg heart ralo vadabllily rmmediately after smoking 
cassatlon. 
~%+ht?Is: In Iho pmsonl study hoatl rata vanability immediately alter 
smoking cessation was invesligled to determine eWec~s al smoking ces. 
salion on autonomic newe activity. Befom and 1. 2. 3. 7. 14. 21. and 28 
days attar smoking cossatron 24.hour liollor eloclrocardiographlc tracings 
were obtained In 20 hoallhy male volunteers (mean age 24.3 years) who had 
smokad .. = 1 pack/day . = 2 years. 
Results: After ono day of smoking cessallon heart rate was signilicanlly 
docmased and alt 24mhour lime and frequency domain indexes of heart rate 
vanability except both the standard deviations of all normal RR Intervals 
and Of I-minute mean RR in the entim 24.hour eloctmcardiographic tracings 
wQl(t increased. The magnitude of increase in these indexes peaked 2 to 
7 days alter smokmg cessalion and gradually decreased thereafter. The 
increase in heart rate vanability persisted a1 1 month of smoking cessation. 
Withdrawal syndrome appeared in 80% of subjects, but it did not affect heart 
rate variability 
COnclUsiOn: Heart rate variablkty rapidl.’ Increased immediale,y after 
smoking cessation. tho magnitude of change reaching a peak aWer 2 to 
7 days and gradually declining thereafter. 
Conclusion: This study suggests that the eWect of smoking on autonomic 
nerve activity rapidly disappears immediately atlet smoking cessation. 
lr.I.3 1625 97 Dltfonncsr Between Local lnvrrtl ator and Con Laboratory tntorprotatlon ot thr A 8 mlBalon 
Eloctrocardlo ram In a Large Multlcenkr Rlal of 
Patlontr Wlth PI nntablo Coronary Artery Dlaonso 
L, Halmvang, P, Hasbak, P. Clammsnasn, P, Orand@. 771# Ifearl Cen@r. 
Fllgsh6wp/fak?f, Cwnhawn Unhrslfy HoWfaI, Wnmrk 
&4ckgrwund: The rtandard twslva lead ECG la an Important prognostiic and 
diagnocllo taol fer evaluntlng patlanta wlth acute sheat pin, Thmugh recent 
yearn tha UIB sf QQm~IabQratQdse (camMa) haa expanded tQ Qnfium II@@ 
pondmt evaluahen al qualltaltve dale tn largar alinical Irialg, II, h~waver, the 
erpnrisnsea lrem theae lrials ahQuld ba sxtrap~laled to “raal~l~fe’ pltuatifma. 
II ia imeertant that ths intammtallQn al data anMs in eotnpambts to I& 
camlab msults. 
A&tW: The study romparea ths admlaskm EC0 data tram SW pabents 
partlalpallng In a large Saandinavifln multi~ntsr trial a( p abents admttted with 
unatabla angina peelafts ar nm+O myaoardlat mfarclm. TM tocal inveati~ 
aatara svaluatad the admisalan ECQ regardmg SM changes beWe lhe 
CCQs were aent TV the corsrlab tm Minded \nlwpmlalion. The strenah\ o( 
agteament be-n the obnervaliana ts bescnbed by Kappa (4 )-stalisaw. 
R6waL: Tbhs Iwal mvealtgalon tdenlttied 17 pal1enI8 wrth ST=s~gment 
alaval!on vsma 91 paltenla HentIlted by the 60~lah (h = 0.05. poor acre 
manl), SVaegmsfM depresstan: 158 patients ~n+iW versus 64 pmlt A 
lha RarMab (L iq 03t!, talc agmemenl)~ %wave invenWn 3pB PeWnt6 on-We 
MIWB 210 camlab (h R 0.63, good agreemen\). Bundte-branch btock: 2t1 
pabsnta were tdentltied anMe vemus lit in the mm-lab (L = 0.85, very good 
agmament). 
lJi~~u;sion: Tha present study coneludes. thet there are consKtemble 
dltterencea between tha on&s interpsCbon al the admisslan ECG and the 
bllnded evakmlian pe~Ion!wd m a cwwlab. llwe drWw?nc8s in ECG mntef- 
pntallons mull be taken mto canstderaVon when epptymg results horn lam 
mulllcenter trials to everyday practice. The tindings undeiiine Ihe tmparlance 
ot oom lab invotvemont o ensure high quakty unbiased analysis ol climcal 
data. 
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1026-65 E$tlmatlng the Llts Years Gained From Preventing 
Cardlovascufar Dlsoase 
J.J. Cam. W.S. Klilltch. For the WOSCOPS Ec~omrc CommmWee. car0 
Researchh. Poston. MA. US?\; Univetstfy of Gtasgole Gtasgow. Scotrand 
Objection: To esllmate the kte years gamed (LYG) by prevention 01 cardlo- 
vascular diseaso (CVD) in subjects without pre-oxcsling disease. 
tI!eW?ods: Survival data were obtained from the Scottish Record Lmkage 
System on all subjects who had suWered a lirst CVD event between 19el 
and 1994. Desphe the large number at palients. this inlormalion prcvlded 
only a small portron of Iha survival curve. Thus. lo fully estimate the cuwe 
and derive LYG projeclions are required. As standard approaches. based 
on a constant hazard. lead lo unreasonable over-estimates. an allemanYe 
molhod was developed. This involved mathematically matching the avadabte 
survival curve tragments lo known full ago and gender-specilic human curves. 
The latter curves were based on life table data. By applying the resultmg 
limo-dependent hazards lo the Scottish data. the full curves were eslrmated. 
Results: The range 01 LYG was from 2.16 (angiography) lo 23.21 (fatal 
CVD events). discounted al 5% per annum. These results am based on 
an group of SO lo 55 year olds. II was eslimaled that the preventron of a 
my@cardral infarction would save about 2.25 years of life and that ol a stroke 
would save 4.53 years. 
Conclusion: As LYG has become the predominant denommator m cost- 
ettecliveness ratios, the proper eslrmation of such is cruaal. Over or under 
estimation may lead lo erroneous conclusions about the economrc efficiency 
of theraoeutic interventrons. 
I 1026 66 Evidence Gased Medicine Needs More Evidence 
J.J. Cam. For the Choice Study Group: Cam Research, Boston. MA. USA 
Many current hypertension management guidelines rely primarily on ev- 
idence ot ellicacy tram clinical trials. The conditions of actual practice. 
however, may diWer signilicanlly from those of clinical trials. To rationally 
choose an antihypertensive agent, a physician must have evidence of rts 
effectiveness. To examine the effectiveness of antihypertensive agents m ac- 
tual practice. the linked health care databases of Saskatchewan. a Canadian 
Chiy pts wffi a hrsto4 of hype&ron-- m&&d. 
. 
I I 
Results: The percentage of pls pfescnb?cJ CCBs. rr bkxkers drurehcs. 
and ACE-i). as mono-or combinabon tfrerapy by year IS shown at right 
CCB use among hypertensms tih fir51 AM1 mcreased drmat~calty (p . 
O.OOl) dunng the stu@y period. such that CCBs were lhe most commonfy 
prescribed agenl after 1993. The advent 01 CC&and ACE-I comcrded v&r an 
overall decrease m fi Mocker and druretrc use. though from 1993-5. foltowrrrg 
pubkcatron of JNC V. thus trend reversed CCEf use appeared unaffected by 
JNC V ncommendatcns. 
ConcIusM: These populahon-hased lmdtngs suggest marked changes 
in practice patterns in hypertensives at nsk for AMI. 
I_-3 1026 68 Active Control Trlats: What About a Placebo? A 
Method lllustratad With Clopldogral. Aspirin and 
Placebo 
L.D. Fisher. Umwrsify of Washrngton Sean/e. WA. USA 
&c@roundr Cardiovascular drug approval IS mcreasmgly dependent on 
active conlml trials for elhical reasons. For regulatory approval it IS necessary 
to rllustrate that a drug would have beaten placebo. Supportwe analyses to 
an active conlml trial(s) are needed in order to estimate what might Cave 
happened it there had been a placebo treatment arm. 
Methods: A new method combmes an active control trial with a number of 
separate placebo contmlled trials against the aclive comparator. The method 
uses the logarithm 01 the odds ratio for the first occurrence of an event and 
estimates: i) the odds ratio for the new dNg versus placebo and ii) a 95% 
confidence interval for the estimate. 
///usriarion: The CAPRIE trial of 75 mg of Clopidogrel versus 325 mg 
of Aspirin studied more lhan 19.000 patients with recent prior ischemic 
Stroke, myWardiaf infamlion or penpheraf edeiiaf ZWaSe. (Lancet. 1996: 
349: 1329-39). Aspirin versus placebo was evaluated in a meta-analysis: 
Anttpfalefel Tnalmr Coflahoralron (W&I. 1994 308 91-108) These TV 
SouKW are used to IllustfalQ the method wtth four ondpomtl, I) thn &dl?f 
01 aft strokes. MI of va~uhr deam: II) 8q m I) pf~ dean from any c~usfj 
III) vsscutar death and IV) cMath tram any cause. ti m~thcd and grap&c 
presentalm of lhe rQrutt8 arQ @WI. estlmatinq m hlehty ataltrfkxffy e 
ncflcant CWdogrel v~mus) placabd resuL (p =’ 00001 for Ike ctuaitsr 0t 
events). Tha 5~~3nl1f1c Cogancy, etrsntxhs and weaknees~a of such anam 
are &sc~sed. 
Lab FacT P-m 
kk.m LOS idaysl 52216 19) 4 I39 13.35) O(wl 
DWEZCI cOnC?ar~~ ss.403 S7.1W 0003 
In cofrdu5100. a large eomofmc beMm wnh0ut dfwxeaf.0 m quality of 
care was noted wtm the use of POCT for management of hepann therapy 
fofklwlng coronary mterverltron 
1026-70 Calcium Charm4 Mockam and Canecr. No 
Evldance of an Increased Risk. 
Samuel Shaprm. Lynn Rosenberg. Bosfon Utnvwmry. lbfon. MA. USA 
83ck9mtmct The qmkrmotcg~~ studtes have suggested that cafckrm &an- 
nel bfocken (CCBs) trmease the risk d several cancers. One study has 
SuggesM lhat CC& may cause breast cancer, and mteract wtth estrogen 
supplements. 
Mefhats In a large ~fmfStL@OfrWlyCZWPXrSconductedhmng 
lse3-199sa~patrents40to69yeandapinhoJpitafJmBslhmns. 
New York and Phtladelphra 9513 cancer cases were compared wlfr 6492 
COlllrdS. 
f+sum; The use of CCEts (mean duratron 3.8 years) was noI -ated 
wrn cancer overall (relattve risk. 1 .l %: 95% conl~r!ence m?erval O.!+-1.3). Nor 
were CCBs assocrafed wttfr mdwrdual cancers, mcfuding ffmse prewously 
rmplrcated. wrM the exceptron of renal cancer. Agam with ffm exception of 
renal cancer. beta-blockers and a~otensmccmterfmg enzyme mhlbrtors 
were also unrelated to cancer mk. Renal cancer has been assoctaled wrth 
hypertensron (and druqs used to treat hypeltennon) m preWou!3 SWdleS. 
Among 2993 cases of breast cancer the relative mk for CCB usa was 1.1 
(95% confidence Interval 0.9-r .4) and there was no evrdence of mteractlcm 
wrth estrogen supplements. 
Conc/usrons: The ftndmgs suggest lhat CC& do not cause cancer 
